Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 698

1.

Chronic lymphocytic leukemia and mantle cell lymphoma: Crossroads of genetic and microenvironment interactions.

Puente XS, Jares P, Campo E.

Blood. 2018 Apr 17. pii: blood-2017-10-764373. doi: 10.1182/blood-2017-10-764373. [Epub ahead of print]

PMID:
29666114
2.

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.

Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM.

N Engl J Med. 2018 Apr 12;378(15):1396-1407. doi: 10.1056/NEJMoa1801445.

PMID:
29641966
3.

High dose rate brachytherapy for prostate cancer: A prospective toxicity evaluation of a one day schedule including two 13.5 Gy fractions.

Nagore G, Lopez Guerra JL, Krumina E, Lagos M, Ovalles B, Miró A, Beltran L, Gómez E, Praena-Fernandez JM, Del Campo ER, Azinovic I, Gomez-Iturriaga A.

Radiother Oncol. 2018 Apr 3. pii: S0167-8140(18)30166-X. doi: 10.1016/j.radonc.2018.03.022. [Epub ahead of print]

PMID:
29625808
4.

A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.

Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Carrère M, Xerri L, Ansell SM, Baseggio L, Reyes C, Tarte K, Boyault S, Haioun C, Link BK, Feugier P, Lopez-Guillermo A, Tilly H, Brice P, Hayette S, Jardin F, Offner F, Sujobert P, Gentien D, Viari A, Campo E, Cerhan JR, Salles G.

Lancet Oncol. 2018 Apr;19(4):549-561. doi: 10.1016/S1470-2045(18)30102-5. Epub 2018 Feb 20.

PMID:
29475724
5.

The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.

Esteve-Arenys A, Valero JG, Chamorro-Jorganes A, Gonzalez D, Rodriguez V, Dlouhy I, Salaverria I, Campo E, Colomer D, Martinez A, Rymkiewicz G, Pérez-Galán P, Lopez-Guillermo A, Roué G.

Oncogene. 2018 Apr;37(14):1830-1844. doi: 10.1038/s41388-017-0111-1. Epub 2018 Jan 22.

PMID:
29353886
6.

Established and suggested exposures on CLL/SLL etiology: Results from the CLL-MCC-Spain study.

Benavente Y, Casabonne D, Costas L, Robles C, Alonso E, de la Banda E, Gonzalez-Barca E, Marcos-Gragera R, Llorca J, Tardón A, Monleon JJ, Aymerich M, Campo E, Gimeno-Vázquez E, Castaño-Vinyals G, Aragonés N, Pollán M, Kogevinas M, de Sanjosé S.

Cancer Epidemiol. 2018 Feb;52:106-111. doi: 10.1016/j.canep.2017.12.012. Epub 2018 Jan 4.

PMID:
29289901
7.

Strain and Bond Length Dynamics upon Growth and Transfer of Graphene by NEXAFS Spectroscopy from First-Principles and Experiment.

Rojas WY, Winter AD, Grote J, Kim SS, Naik RR, Williams AD, Weiland C, Principe E, Fischer DA, Banerjee S, Prendergast D, Campo EM.

Langmuir. 2018 Jan 30;34(4):1783-1794. doi: 10.1021/acs.langmuir.7b03260. Epub 2018 Jan 18.

PMID:
29286662
8.

Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.

Arcaini L, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F, Alexeeva J, Rule S, Cabeçadas J, Campo E, Pileri SA, Biyukov T, Patturajan M, Casadebaig Bravo ML, Trnĕný M; SPRINT Trial Investigators.

Br J Haematol. 2018 Jan;180(2):224-235. doi: 10.1111/bjh.15025. Epub 2017 Nov 28.

9.

Climate change and water management in the biblical city of Dan.

Kaniewski D, Marriner N, Ilan D, Morhange C, Thareani Y, Van Campo E.

Sci Adv. 2017 Nov 22;3(11):e1700954. doi: 10.1126/sciadv.1700954. eCollection 2017 Nov.

10.

Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups.

Burns A, Alsolami R, Becq J, Stamatopoulos B, Timbs A, Bruce D, Robbe P, Vavoulis D, Clifford R, Cabes M, Dreau H, Taylor J, Knight SJL, Mansson R, Bentley D, Beekman R, Martín-Subero JI, Campo E, Houlston RS, Ridout KE, Schuh A.

Leukemia. 2018 Feb;32(2):573. doi: 10.1038/leu.2017.311. Epub 2017 Nov 21.

11.

Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group.

Nomdedeu M, Pereira A, Calvo X, Colomer J, Sole F, Arias A, Gomez C, Luño E, Cervera J, Arnan M, Pomares H, Ramos F, Oiartzabal I, Espinet B, Pedro C, Arrizabalaga B, Blanco ML, Tormo M, Hernandez-Rivas JM, Díez-Campelo M, Ortega M, Valcárcel D, Cedena MT, Collado R, Grau J, Granada I, Sanz G, Campo E, Esteve J, Costa D; Spanish MDS Group.

Leuk Res. 2017 Dec;63:85-89. doi: 10.1016/j.leukres.2017.10.011. Epub 2017 Oct 28.

PMID:
29121539
12.

The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.

Martínez-Trillos A, Pinyol M, Delgado J, Aymerich M, Rozman M, Baumann T, González-Díaz M, Hernández JM, Alcoceba M, Muntañola A, Terol MJ, Navarro B, Giné E, Jares P, Beà S, Navarro A, Colomer D, Nadeu F, Colado E, Payer AR, García-Cerecedo T, Puente XS, López-Otin C, Campo E, López-Guillermo A, Villamor N.

Leuk Lymphoma. 2017 Nov 8:1-9. doi: 10.1080/10428194.2017.1397660. [Epub ahead of print]

PMID:
29115891
13.

Origin and evolution of chloroplast group I introns in lichen algae.

Del Hoyo A, Álvarez R, Gasulla F, Casano LM, Del Campo EM.

J Phycol. 2018 Feb;54(1):66-78. doi: 10.1111/jpy.12600. Epub 2017 Nov 29.

PMID:
29057470
14.

Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma.

Magnano L, Balagué O, Dlouhy I, Rovira J, Karube K, Pinyol M, Rivas-Delgado A, Costa D, Martínez-Trillos A, González-Farre B, Martínez-Pozo A, Giné E, Colomer D, Delgado J, Villamor N, Campo E, López-Guillermo A.

Ann Oncol. 2017 Nov 1;28(11):2799-2805. doi: 10.1093/annonc/mdx407.

PMID:
29045517
15.

Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.

Miyaoka M, Kikuti YY, Carreras J, Ikoma H, Hiraiwa S, Ichiki A, Kojima M, Ando K, Yokose T, Sakai R, Hoshikawa M, Tomita N, Miura I, Takata K, Yoshino T, Takizawa J, Bea S, Campo E, Nakamura N.

Mod Pathol. 2018 Feb;31(2):313-326. doi: 10.1038/modpathol.2017.134. Epub 2017 Oct 6.

PMID:
28984304
16.

Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia.

Nadeu F, Clot G, Delgado J, Martín-García D, Baumann T, Salaverria I, Beà S, Pinyol M, Jares P, Navarro A, Suárez-Cisneros H, Aymerich M, Rozman M, Villamor N, Colomer D, González M, Alcoceba M, Terol MJ, Navarro B, Colado E, Payer ÁR, Puente XS, López-Otín C, López-Guillermo A, Enjuanes A, Campo E.

Leukemia. 2018 Mar;32(3):645-653. doi: 10.1038/leu.2017.291. Epub 2017 Sep 19.

17.

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, Shpilberg O, Walewski J, Ladetto M; ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv62-iv71. doi: 10.1093/annonc/mdx223. No abstract available.

PMID:
28881919
18.

The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.

Vidal-Crespo A, Rodriguez V, Matas-Cespedes A, Lee E, Rivas-Delgado A, Giné E, Navarro A, Beà S, Campo E, López-Guillermo A, Lopez-Guerra M, Roué G, Colomer D, Pérez-Galán P.

Haematologica. 2017 Nov;102(11):e447-e451. doi: 10.3324/haematol.2017.168930. Epub 2017 Aug 24. No abstract available.

19.

Is there a role for minimal residual disease monitoring in the management of patients with hairy-cell leukaemia?

Ortiz-Maldonado V, Villamor N, Baumann T, Aymerich M, Magnano L, Mozas P, Rivas-Delgado A, Martínez-Trillos A, Giné E, Campo E, López-Guillermo A, Delgado J.

Br J Haematol. 2017 Aug 18. doi: 10.1111/bjh.14900. [Epub ahead of print] No abstract available.

PMID:
28832940
20.

Shelterins, a genetic crossroad in CLL.

Beekman R, Campo E.

Blood. 2016 Nov 10;128(19):2279-2280. doi: 10.1182/blood-2016-09-735688. No abstract available.

21.

Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.

Karube K, Enjuanes A, Dlouhy I, Jares P, Martin-Garcia D, Nadeu F, Ordóñez GR, Rovira J, Clot G, Royo C, Navarro A, Gonzalez-Farre B, Vaghefi A, Castellano G, Rubio-Perez C, Tamborero D, Briones J, Salar A, Sancho JM, Mercadal S, Gonzalez-Barca E, Escoda L, Miyoshi H, Ohshima K, Miyawaki K, Kato K, Akashi K, Mozos A, Colomo L, Alcoceba M, Valera A, Carrió A, Costa D, Lopez-Bigas N, Schmitz R, Staudt LM, Salaverria I, López-Guillermo A, Campo E.

Leukemia. 2018 Mar;32(3):675-684. doi: 10.1038/leu.2017.251. Epub 2017 Aug 14.

22.

Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets.

Bouska A, Bi C, Lone W, Zhang W, Kedwaii A, Heavican T, Lachel CM, Yu J, Ferro R, Eldorghamy N, Greiner TC, Vose J, Weisenburger DD, Gascoyne RD, Rosenwald A, Ott G, Campo E, Rimsza LM, Jaffe ES, Braziel RM, Siebert R, Miles RR, Dave S, Reddy A, Delabie J, Staudt LM, Song JY, McKeithan TW, Fu K, Green M, Chan WC, Iqbal J.

Blood. 2017 Oct 19;130(16):1819-1831. doi: 10.1182/blood-2017-02-767335. Epub 2017 Aug 11.

PMID:
28801451
23.

Pathology and classification of aggressive mature B-cell lymphomas.

Campo E.

Hematol Oncol. 2017 Jun;35 Suppl 1:80-83. doi: 10.1002/hon.2406. No abstract available.

PMID:
28591413
24.

Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups.

Burns A, Alsolami R, Becq J, Stamatopoulos B, Timbs A, Bruce D, Robbe P, Vavoulis D, Clifford R, Cabes M, Dreau H, Taylor J, Knight SJL, Mansson R, Bentley D, Beekman R, Martín-Subero JI, Campo E, Houlston RS, Ridout KE, Schuh A.

Leukemia. 2018 Feb;32(2):332-342. doi: 10.1038/leu.2017.177. Epub 2017 Jun 6. Erratum in: Leukemia. 2017 Nov 21;:.

25.

Expression of a truncated B lymphocyte-induced maturation protein-1 isoform is associated with an incomplete plasmacytic differentiation program in chronic lymphocytic leukemia.

Solé C, Martínez D, Giné E, Gonzalez-Farre B, Pérez-Galán P, Roncador G, Campo E, Matutes E, López-Guillermo A, Roué G, Martínez A.

Leuk Lymphoma. 2018 Feb;59(2):482-485. doi: 10.1080/10428194.2017.1330470. Epub 2017 Jun 2. No abstract available.

PMID:
28573896
26.

High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma.

Dlouhy I, Filella X, Rovira J, Magnano L, Rivas-Delgado A, Baumann T, Martínez-Trillos A, Balagué O, Martínez A, González-Farre B, Karube K, Gine E, Delgado J, Campo E, López-Guillermo A.

Leuk Res. 2017 Aug;59:20-25. doi: 10.1016/j.leukres.2017.05.014. Epub 2017 May 17.

PMID:
28544905
27.

Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes.

Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton LA, Minga E, Ntoufa S, Tausch E, Yan XJ, Shanafelt T, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfo L, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan-Djurasevic T, Catherwood M, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc MP, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antic D, Trentin L, Montillo M, Niemann C, Döhner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek DF, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K.

Clin Cancer Res. 2017 Sep 1;23(17):5292-5301. doi: 10.1158/1078-0432.CCR-16-3100. Epub 2017 May 23.

PMID:
28536306
28.

Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation.

Schmidt J, Ramis-Zaldivar JE, Nadeu F, Gonzalez-Farre B, Navarro A, Egan C, Montes-Mojarro IA, Marafioti T, Cabeçadas J, van der Walt J, Dojcinov S, Rosenwald A, Ott G, Bonzheim I, Fend F, Campo E, Jaffe ES, Salaverria I, Quintanilla-Martinez L.

Blood. 2017 Jul 20;130(3):323-327. doi: 10.1182/blood-2017-03-776278. Epub 2017 May 22.

PMID:
28533310
29.

SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.

Balsas P, Palomero J, Eguileor Á, Rodríguez ML, Vegliante MC, Planas-Rigol E, Sureda-Gómez M, Cid MC, Campo E, Amador V.

Blood. 2017 Jul 27;130(4):501-513. doi: 10.1182/blood-2017-04-776740. Epub 2017 May 22.

PMID:
28533307
30.

Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier.

Navarro A, Clot G, Martínez-Trillos A, Pinyol M, Jares P, González-Farré B, Martínez D, Trim N, Fernández V, Villamor N, Colomer D, Costa D, Salaverria I, Martín-Garcia D, Erber W, López C, Jayne S, Siebert R, Dyer MJS, Wiestner A, Wilson WH, Aymerich M, López-Guillermo A, Sánchez À, Campo E, Matutes E, Beà S.

Haematologica. 2017 Sep;102(9):e360-e363. doi: 10.3324/haematol.2016.160374. Epub 2017 May 18. No abstract available.

31.

Numerous Ontogenetic Roads to Mantle Cell Lymphoma: Immunogenetic and Immunohistochemical Evidence.

Pouliou E, Xochelli A, Kanellis G, Stalika E, Sutton LA, Navarro A, Agathangelidis A, Dimosthenous K, Anagnostopoulos A, Patsouris E, Korkolopoulou P, Sundstrom C, Ghia P, Ponzoni M, Sander B, Campo E, Rosenquist R, Hadzidimitriou A, Stamatopoulos K, Papadaki T.

Am J Pathol. 2017 Jul;187(7):1454-1458. doi: 10.1016/j.ajpath.2017.02.017. Epub 2017 Apr 28.

PMID:
28457696
32.

Refining the prognostic impact of the cell of origin in diffuse large B-cell lymphoma.

Balagué O, Campo E.

Ann Oncol. 2017 May 1;28(5):918-920. doi: 10.1093/annonc/mdx133. No abstract available.

PMID:
28368451
33.

Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma.

Balsas P, Esteve-Arenys A, Roldán J, Jiménez L, Rodríguez V, Valero JG, Chamorro-Jorganes A, de la Bellacasa RP, Teixidó J, Matas-Céspedes A, Moros A, Martínez A, Campo E, Sáez-Borderías A, Borrell JI, Pérez-Galán P, Colomer D, Roué G.

J Hematol Oncol. 2017 Mar 31;10(1):80. doi: 10.1186/s13045-017-0447-6.

34.

Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.

Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C.

J Clin Oncol. 2017 Jun 10;35(17):1905-1912. doi: 10.1200/JCO.2016.70.6994. Epub 2017 Mar 29.

PMID:
28355112
35.

Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma.

Höring E, Montraveta A, Heine S, Kleih M, Schaaf L, Vöhringer MC, Esteve-Arenys A, Roué G, Colomer D, Campo E, Ott G, Aulitzky WE, van der Kuip H.

Br J Haematol. 2017 May;177(4):557-561. doi: 10.1111/bjh.14571. Epub 2017 Mar 14.

PMID:
28295185
36.

New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies.

Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok A, Villa D, Jares P, Rauert-Wunderlich H, Royo C, Clot G, Pinyol M, Boyle M, Chan FC, Braziel RM, Chan WC, Weisenburger DD, Cook JR, Greiner TC, Fu K, Ott G, Delabie J, Smeland EB, Holte H, Jaffe ES, Steidl C, Connors JM, Gascoyne RD, Rosenwald A, Staudt LM, Campo E, Rimsza LM; Lymphoma/Leukemia Molecular Profiling Project.

J Clin Oncol. 2017 May 20;35(15):1668-1677. doi: 10.1200/JCO.2016.70.7901. Epub 2017 Mar 14.

PMID:
28291392
37.

LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.

Colomo L, Vazquez I, Papaleo N, Espinet B, Ferrer A, Franco C, Comerma L, Hernandez S, Calvo X, Salar A, Climent F, Mate JL, Forcada P, Mozos A, Nonell L, Martinez A, Carrio A, Costa D, Dlouhy I, Salaverria I, Martin-Subero JI, Lopez-Guillermo A, Valera A, Campo E; Grup per l’Estudi dels Limfomes de Catalunya i Balears (GELCAB).

Am J Surg Pathol. 2017 Jul;41(7):877-886. doi: 10.1097/PAS.0000000000000839.

PMID:
28288039
38.

Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia.

Law PJ, Berndt SI, Speedy HE, Camp NJ, Sava GP, Skibola CF, Holroyd A, Joseph V, Sunter NJ, Nieters A, Bea S, Monnereau A, Martin-Garcia D, Goldin LR, Clot G, Teras LR, Quintela I, Birmann BM, Jayne S, Cozen W, Majid A, Smedby KE, Lan Q, Dearden C, Brooks-Wilson AR, Hall AG, Purdue MP, Mainou-Fowler T, Vajdic CM, Jackson GH, Cocco P, Marr H, Zhang Y, Zheng T, Giles GG, Lawrence C, Call TG, Liebow M, Melbye M, Glimelius B, Mansouri L, Glenn M, Curtin K, Diver WR, Link BK, Conde L, Bracci PM, Holly EA, Jackson RD, Tinker LF, Benavente Y, Boffetta P, Brennan P, Maynadie M, McKay J, Albanes D, Weinstein S, Wang Z, Caporaso NE, Morton LM, Severson RK, Riboli E, Vineis P, Vermeulen RC, Southey MC, Milne RL, Clavel J, Topka S, Spinelli JJ, Kraft P, Ennas MG, Summerfield G, Ferri GM, Harris RJ, Miligi L, Pettitt AR, North KE, Allsup DJ, Fraumeni JF, Bailey JR, Offit K, Pratt G, Hjalgrim H, Pepper C, Chanock SJ, Fegan C, Rosenquist R, de Sanjose S, Carracedo A, Dyer MJ, Catovsky D, Campo E, Cerhan JR, Allan JM, Rothman N, Houlston R, Slager S.

Nat Commun. 2017 Feb 6;8:14175. doi: 10.1038/ncomms14175.

39.

Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing.

Lorenzi L, Döring C, Rausch T, Benes V, Lonardi S, Bugatti M, Campo E, Cabeçadas J, Simonitsch-Klupp I, Borges A, Mehta J, Agostinelli C, Pileri SA, Facchetti F, Hansmann ML, Hartmann S.

Oncotarget. 2017 Mar 7;8(10):16463-16472. doi: 10.18632/oncotarget.14864.

40.

Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell Sarcomas.

Laginestra MA, Tripodo C, Agostinelli C, Motta G, Hartmann S, Döring C, Rossi M, Melle F, Sapienza MR, Tabanelli V, Pileri A, Fuligni F, Gazzola A, Mannu C, Sagramoso CA, Lonardi S, Lorenzi L, Bacci F, Sabattini E, Borges A, Simonitsch-Klupp I, Cabecadas J, Campo E, Rosai J, Hansmann ML, Facchetti F, Pileri SA.

Mol Cancer Res. 2017 May;15(5):541-552. doi: 10.1158/1541-7786.MCR-16-0301. Epub 2017 Jan 27.

PMID:
28130401
41.

Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial.

Magnano L, Montoto S, González-Barca E, Briones J, Sancho JM, Muntañola A, Salar A, Besalduch J, Escoda L, Moreno C, Domingo-Domenech E, Estany C, Oriol A, Altés A, Pedro C, Gardella S, Asensio A, Vivancos P, Fernández de Sevilla A, Ribera JM, Colomer D, Campo E, López-Guillermo A.

Ann Hematol. 2017 Apr;96(4):639-646. doi: 10.1007/s00277-017-2920-2. Epub 2017 Jan 18.

PMID:
28101592
42.

HHV8-related lymphoid proliferations: a broad spectrum of lesions from reactive lymphoid hyperplasia to overt lymphoma.

Gonzalez-Farre B, Martinez D, Lopez-Guerra M, Xipell M, Monclus E, Rovira J, Garcia F, Lopez-Guillermo A, Colomo L, Campo E, Martinez A.

Mod Pathol. 2017 May;30(5):745-760. doi: 10.1038/modpathol.2016.233. Epub 2017 Jan 13.

PMID:
28084335
43.

Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas.

Abate F, da Silva-Almeida AC, Zairis S, Robles-Valero J, Couronne L, Khiabanian H, Quinn SA, Kim MY, Laginestra MA, Kim C, Fiore D, Bhagat G, Piris MA, Campo E, Lossos IS, Bernard OA, Inghirami G, Pileri S, Bustelo XR, Rabadan R, Ferrando AA, Palomero T.

Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):764-769. doi: 10.1073/pnas.1608839114. Epub 2017 Jan 6.

44.

Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Dlouhy I, Torrente MÁ, Lens S, Rovira J, Magnano L, Giné E, Delgado J, Balagué O, Martínez A, Campo E, Forns X, Sánchez-Tapias JM, López-Guillermo A.

Ann Hematol. 2017 Mar;96(3):405-410. doi: 10.1007/s00277-016-2903-8. Epub 2016 Dec 29.

PMID:
28035434
45.

Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage.

Queirós AC, Beekman R, Vilarrasa-Blasi R, Duran-Ferrer M, Clot G, Merkel A, Raineri E, Russiñol N, Castellano G, Beà S, Navarro A, Kulis M, Verdaguer-Dot N, Jares P, Enjuanes A, Calasanz MJ, Bergmann A, Vater I, Salaverría I, van de Werken HJG, Wilson WH, Datta A, Flicek P, Royo R, Martens J, Giné E, Lopez-Guillermo A, Stunnenberg HG, Klapper W, Pott C, Heath S, Gut IG, Siebert R, Campo E, Martín-Subero JI.

Cancer Cell. 2016 Nov 14;30(5):806-821. doi: 10.1016/j.ccell.2016.09.014.

46.

Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).

Carreras J, Kikuti YY, Beà S, Miyaoka M, Hiraiwa S, Ikoma H, Nagao R, Tomita S, Martin-Garcia D, Salaverria I, Sato A, Ichiki A, Roncador G, Garcia JF, Ando K, Campo E, Nakamura N.

Histopathology. 2017 Mar;70(4):595-621. doi: 10.1111/his.13106. Epub 2017 Jan 9.

PMID:
27775850
47.

Genetic evolution in chronic lymphocytic leukaemia.

Delgado J, Villamor N, López-Guillermo A, Campo E.

Best Pract Res Clin Haematol. 2016 Mar;29(1):67-78. doi: 10.1016/j.beha.2016.08.003. Epub 2016 Aug 11. Review.

PMID:
27742073
48.

T-cell subsets in lymph nodes identify a subgroup of follicular lymphoma patients with favorable outcome.

Magnano L, Martínez A, Carreras J, Martínez-Trillos A, Giné E, Rovira J, Dlouhy I, Baumann T, Balagué O, Campo E, López-Guillermo A, Villamor N.

Leuk Lymphoma. 2017 Apr;58(4):842-850. doi: 10.1080/10428194.2016.1217525. Epub 2016 Aug 11.

PMID:
27687692
49.

Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma.

Mansouri L, Noerenberg D, Young E, Mylonas E, Abdulla M, Frick M, Asmar F, Ljungström V, Schneider M, Yoshida K, Skaftason A, Pandzic T, Gonzalez B, Tasidou A, Waldhueter N, Rivas-Delgado A, Angelopoulou M, Ziepert M, Arends CM, Couronné L, Lenze D, Baldus CD, Bastard C, Okosun J, Fitzgibbon J, Dörken B, Drexler HG, Roos-Weil D, Schmitt CA, Munch-Petersen HD, Zenz T, Hansmann ML, Strefford JC, Enblad G, Bernard OA, Ralfkiaer E, Erlanson M, Korkolopoulou P, Hultdin M, Papadaki T, Grønbæk K, Lopez-Guillermo A, Ogawa S, Küppers R, Stamatopoulos K, Stavroyianni N, Kanellis G, Rosenwald A, Campo E, Amini RM, Ott G, Vassilakopoulos TP, Hummel M, Rosenquist R, Damm F.

Blood. 2016 Dec 8;128(23):2666-2670. Epub 2016 Sep 26.

50.

The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.

Matas-Céspedes A, Vidal-Crespo A, Rodriguez V, Villamor N, Delgado J, Giné E, Roca-Ho H, Menéndez P, Campo E, López-Guillermo A, Colomer D, Roué G, Wiestner A, Parren PW, Doshi P, van Bueren JL, Pérez-Galán P.

Clin Cancer Res. 2017 Mar 15;23(6):1493-1505. doi: 10.1158/1078-0432.CCR-15-2095. Epub 2016 Sep 16.

Supplemental Content

Support Center